Status:
COMPLETED
JAB-3312 Based Combination Therapy in Adult Patients With Advanced Solid Tumors
Lead Sponsor:
Allist Pharmaceuticals, Inc.
Collaborating Sponsors:
AbbVie
Conditions:
Solid Tumor
NSCLC
Eligibility:
All Genders
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
To evaluate the safety and tolerability of JAB-3312 administered in investigational regimens in adult participants with advanced solid tumors.
Detailed Description
To assess the safety and tolerability and determine the Recommended phase 2 dose (RP2D) of JAB-3312 in combination with PD1 inhibitor or MEK inhibitor in patients with advanced solid tumors.
Eligibility Criteria
Inclusion
- Must have histologically or cytologically confirmed metastatic or locally advanced solid tumor. Some cohorts must meet specific expression or gene mutation where indicated
- Sufficient organ function
- Participants must have at least 1 measurable lesion as defined by RECIST v1.1
- Must be able to provide an archived tumor sample
- ECOG performance status score of 0 or 1.
Exclusion
- History of cancer that is histologically distinct from the cancers under study
- Active or untreated central nervous system (CNS) metastases
- History of pneumonitis or interstitial lung disease (ILD)
- Has active hepatitis B, hepatitis C infection, HIV
- Any severe and/or uncontrolled medical conditions
- LVEF ≤50%
- QTcF \>470 msec
Key Trial Info
Start Date :
March 23 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 19 2023
Estimated Enrollment :
58 Patients enrolled
Trial Details
Trial ID
NCT04720976
Start Date
March 23 2021
End Date
December 19 2023
Last Update
April 11 2025
Active Locations (15)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Phoenix, Arizona, United States, 85054
2
Research Site
Scottsdale, Arizona, United States, 85259
3
Research Site
Los Angeles, California, United States, 90033
4
Research Site
New Haven, Connecticut, United States, 06510